Press releases

Regulatory

May 24, 2022

Nanoform 1Q 2022 report: Quarterly record of new projects and new customers

Non Regulatory

May 10, 2022

Invitation to Nanoform’s Interim Report January-March 2022

Non Regulatory

May 4, 2022

Nanoform launches “STARMAP[®] Online” placing AI-power at the fingertips of medicine developers

Regulatory

April 12, 2022

Nanoform Finland Plc – Manager’s transactions – Gonçalo Andrade

Regulatory

April 12, 2022

Nanoform Finland Plc – Manager’s transactions – Niklas Sandler

Regulatory

April 12, 2022

Share subscriptions based on Nanoform Finland Plc’s multiple Stock Option Programs

Regulatory

April 12, 2022

Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc

Regulatory

April 12, 2022

Resolutions of Nanoform Finland Plc’s Annual General Meeting on April 12, 2022

Regulatory

March 25, 2022

Nanoform Finland Plc – Manager’s transactions – Gonçalo Andrade

Regulatory

March 23, 2022

New shares of Nanoform registered with the trade register

Regulatory

March 22, 2022

Nanoform successfully completes new share issue raising EUR 25 million to prepare for GMP manufacturing in the USA

Regulatory

March 22, 2022

Nanoform announces its intention to carry out a new share issue to raise approximately EUR 25 million to prepare for GMP manufacturing in the USA

Regulatory

March 17, 2022

Notice to the Annual General Meeting of NANOFORM FINLAND Plc

Regulatory

March 17, 2022

Kutsu Nanoform Finland Oyj:n varsinaiseen yhtiökokoukseen

Regulatory

February 22, 2022

Nanoform 4Q and full year 2021 report: accelerating GMP growth

Non Regulatory

February 8, 2022

Invitation to Nanoform’s Q4 and full year 2021 report February 22, 2022

Non Regulatory

February 4, 2022

Nanoform signs GMP manufacturing program with TargTex following formulation success

Regulatory

January 3, 2022

Nanoform sets two new near-term business targets for 2022

Regulatory

December 10, 2021

Nanoform financial calendar for 2022

Regulatory

November 25, 2021

Nanoform Interim Report January – September 2021

Regulatory

November 17, 2021

Resolutions of Nanoform Finland Plc’s Extraordinary General Meeting on November 17, 2021

Non Regulatory

November 17, 2021

Nanoform wins Star of Innovation award at the European Small and Mid-Cap Awards 2021

Regulatory

November 15, 2021

Nanoform signs GMP agreement and achieves near-term business target

Non Regulatory

November 12, 2021

Nanoform receives ISO/IEC 27001:2013 certification for its Information Security Management System

Non Regulatory

November 11, 2021

Invitation to presentation of Nanoform’s Q3/2021 report on November 25, 2021

Regulatory

October 18, 2021

Nanoform convenes EGM to elect Jeanne Thoma as board member

Regulatory

October 18, 2021

Notice to the Extraordinary General Meeting of NANOFORM FINLAND PLC

Regulatory

October 18, 2021

Kutsu Nanoform Finland OyJ:n ylimääräiseen yhtiökokoukseen

Non Regulatory

September 29, 2021

Nanoform receives funding to solve challenges for global health

Regulatory

September 24, 2021

Nanoform Finland Plc – Manager’s transactions – Gonçalo Andrade

Non Regulatory

September 23, 2021

Nanoform shortlisted for the European Small and Mid-Cap Awards 2021

Non Regulatory

September 9, 2021

Nanoform technology delivers successful results for Herantis CDNF drug candidate

Regulatory

August 27, 2021

The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees

Regulatory

August 26, 2021

Nanoform Interim Report January – June 2021

Non Regulatory

August 12, 2021

Invitation to presentation of Nanoform’s Q2/2021 report on August 26, 2021

Non Regulatory

August 3, 2021

Nanoform and Boehringer Ingelheim execute master services agreement

Regulatory

June 14, 2021

Nanoform Finland Plc – Manager’s transactions – Gonçalo Andrade

Regulatory

June 11, 2021

The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees

Regulatory

June 11, 2021

Share subscriptions based on Nanoform Finland Plc’s multiple Stock Option Programs

Regulatory

June 2, 2021

Nanoform raises its mid-term business targets for 2025

Regulatory

May 27, 2021

Nanoform Interim Report January – March (Q1) 2021

Non Regulatory

May 25, 2021

Nanoform and Celanese Explore Ways to Enhance Drug Delivery

Regulatory

May 20, 2021

Cynthia Schwalm transitions to Senior Advisor Business Development US, from her role as member of the Board of Directors

Non Regulatory

May 18, 2021

Nanoform’s final clinical results confirm value proposition to the pharma industry

Non Regulatory

May 12, 2021

Invitation to presentation of Nanoform’s Q1/2021 report on May 27, 2021

Regulatory

May 11, 2021

The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees

Non Regulatory

April 21, 2021

Nanoform and Aprecia collaborate to advance 3D printed Nanomedicines

Regulatory

April 8, 2021

Nanoform Finland Plc – Manager’s transactions – Gonçalo Andrade

Regulatory

April 7, 2021

Share subscriptions based on Nanoform Finland Plc’s multiple Stock Option Programs

Regulatory

April 6, 2021

Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc

Regulatory

April 6, 2021

Resolutions of Nanoform Finland Plc’s Annual General Meeting on April 6, 2021

Non Regulatory

March 31, 2021

Nanoform and Nacuity Pharmaceuticals Sign Technology Proof of Concept (“PoC”) Agreement for Two Ophthalmic Drug Candidates

Non Regulatory

March 22, 2021

Nanoform launches next-generation STARMAP^® v2.0, the AI-based drug candidate selection tool for CESS^®

Regulatory

March 10, 2021

NOTICE TO THE ANNUAL GENERAL MEETING OF NANOFORM FINLAND PLC

Regulatory

March 10, 2021

Kutsu Nanoform Finland Oyj:n varsinaiseen yhtiökokoukseen

Regulatory

March 10, 2021

Nanoform Finland Plc: 5 633 803 new shares registered with the trade register

Regulatory

March 9, 2021

Nanoform Finland Plc successfully completes new share issue raising EUR 40 million

Regulatory

March 9, 2021

Nanoform Finland Plc announces its intention to carry out a new share issue to raise approximately EUR 40 million

Regulatory

February 26, 2021

Nanoform 1-12/2020 report and new company near-term target introduced

Regulatory

February 26, 2021

Nanoform sets new near-term business target for 2021 and 2022

Regulatory

February 24, 2021

Additional Positive Interim Results from Nanoform’s Clinical Study

Non Regulatory

February 12, 2021

Invitation to presentation of Nanoform’s year-end report for 2020 on February 26, 2021

Non Regulatory

February 9, 2021

Nanoform and Herantis sign Biologics Proof of Concept Agreement

Regulatory

January 22, 2021

Nanoform’s Clinical Study Indicates Positive Interim Results

Non Regulatory

January 11, 2021

Finnish Foundation for Share Promotion and Nasdaq Helsinki has chosen Nanoform as the company of the month (article in Finnish)

Regulatory

January 4, 2021

Nanoform sets a new near-term business target for 2021

Non Regulatory

December 23, 2020

Nanoform included in Nasdaq First North 25 index as of Jan 4th, 2021

Non Regulatory

December 21, 2020

First dosing of nanoformed drug successfully accomplished

Regulatory

December 17, 2020

Nanoform and Herantis partner to look for opportunities to enhance BBB penetration of CDNF and xCDNF molecules

Non Regulatory

December 8, 2020

Notification of major shareholdings according to Nanoform’s Articles of Association

Non Regulatory

December 2, 2020

Nanoform makes US TV debut in Advancements with Ted Danson (CNBC)

Regulatory

November 27, 2020

Nanoform Finland Plc, Interim Report January – September 2020, November 27[th], 2020 at 08:00 a.m. Finnish time

Regulatory

November 27, 2020

Nanoform launches technology for biologics and sets new near-term business target for 2021

Non Regulatory

November 16, 2020

Invitation to presentation of Nanoform’s Q3 Report on November 27

Non Regulatory

November 11, 2020

Nanoform to present at Avanza Börsdag on November 18

Regulatory

October 23, 2020

The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees

Regulatory

October 20, 2020

Nanoform initiates GMP campaign for first-in-human trial of nanoformed drug by year end – ahead of schedule

Regulatory

September 2, 2020

Nanoform Finland Plc – Manager’s transactions – Goncalo Andrade

Regulatory

September 2, 2020

Share subscriptions based on Nanoform Finland Plc’s 2/2019 and 1/2020 Stock Option Programs

Non Regulatory

September 1, 2020

Nanoform expands global commercial team with US appointments

Regulatory

September 1, 2020

Resolutions of Nanoform Finland Plc’s Extraordinary General Meeting and Board of Directors on September 1, 2020

Regulatory

August 28, 2020

NANOFORM FINLAND PLC, 2020 HALF YEAR FINANCIAL REPORT, 28 AUGUST 2020 AT 8:10 AM EEST

Regulatory

August 6, 2020

Kutsu Nanoform Finland OyJ:n ylimääräiseen yhtiökokoukseen

Regulatory

August 6, 2020

Notice to the extraordinary General Meeting of NANOFORM FINLAND PLC

Regulatory

August 6, 2020

Nanoform convenes EGM to elect Cynthia Schwalm as board member

Non Regulatory

July 9, 2020

Nanoform’s positive commercial momentum continues

Regulatory

June 25, 2020

The Board of Directors of Nanoform Finland Plc decided on issue of stock options to key employees

Non Regulatory

June 15, 2020

Nanoform Finland Plc appoints Peter Hänninen as General Counsel

Regulatory

June 10, 2020

Nanoform Finland Plc – Manager’s transactions – Edward Hæggström

Regulatory

June 10, 2020

Nanoform Finland Plc – Manager’s transactions – Albert Hæggström

Regulatory

June 10, 2020

Exercise of over-allotment option in relation to the initial public offering of Nanoform Finland Plc and termination of the stabilization period

Regulatory

June 10, 2020

Nanoform Finland Oyj:n listautumisannin lisäosakeoption toteuttaminen ja vakauttamisajan päättäminen

Regulatory

June 10, 2020

Utnyttjande av övertilldelningsoptionen i noteringen av Nanoform Finland Plc och avbrytande av stabiliseringsperioden

Regulatory

June 9, 2020

De tio största aktieägarna i Nanoform Finland Plc efter genomförandet av noteringen

Regulatory

June 9, 2020

Nanoform Finland Plc’s ten largest shareholders after the completion of the Initial Public Offering

Regulatory

June 9, 2020

Nanoform Finland Oyj:n kymmenen suurinta osakkeenomistajaa listautumisannin päättymisen jälkeen

Regulatory

June 3, 2020

Erbjudandet i samband med noteringen av Nanoform har kraftigt övertecknats och kommer att genomföras som planerat – handel i aktierna förväntas inledas imorgon

Regulatory

June 3, 2020

The IPO of Nanoform has been considerably oversubscribed and the listing will be completed as planned – trading in the shares is expected to commence tomorrow

Regulatory

June 3, 2020

Nanoformin listautumisanti on huomattavasti ylimerkitty ja listautuminen toteutetaan suunnitellusti – osakkeiden kaupankäynnin odotetaan alkavan huomenna

Regulatory

June 2, 2020

The institutional offering of Nanoform has been considerably oversubscribed and therefore the subscription period has been closed

Regulatory

June 2, 2020

Nanoformin Instituutioanti on huomattavasti ylimerkitty ja tämän takia merkintäaika on päätetty

Regulatory

June 2, 2020

Det institutionella erbjudandet i Nanoform är kraftigt övertecknat och teckningsperioden har därmed avslutats

Regulatory

June 1, 2020

Nanoformin Yleisöanti on huomattavasti ylimerkitty ja tämän takia merkintäaika on päätetty

Regulatory

June 1, 2020

Erbjudandet i samband med noteringen av Nanoform är kraftigt övertecknat och teckningsperioden har därmed avslutats

Regulatory

June 1, 2020

Public offering of Nanoform has been considerably oversubscribed and therefore the subscription period has been closed

Regulatory

May 28, 2020

Nanoform Finland Plc har ansökt om upptagande till handel av dess aktier på Nasdaq First North Premier Growth Market Finland och Nasdaq First North Premier Growth Market Sweden

Regulatory

May 28, 2020

Nanoform Finland Oyj on hakenut osakkeidensa listausta Nasdaq First North Premier Growth Market Finlandissa ja Nasdaq First North Premier Growth Market Swedenissä

Regulatory

May 28, 2020

Nanoform Finland Plc has applied for its shares to be listed on Nasdaq First North Premier Growth Market Finland and Nasdaq First North Premier Growth Market Sweden

Regulatory

May 25, 2020

Nanoform offentliggör en fast teckningskurs och publicerar ett prospekt för den planerade parallellnoteringen av dess aktier på Nasdaq First North Premier Growth Market i Finland & Sverige

Regulatory

May 25, 2020

Nanoform julkistaa suunnitellun listautumisantinsa kiinteän merkintähinnan sekä esitteen liittyen kaksoislistautumiseensa Nasdaq First North Premier Growth Market -markkinapaikoille Suomessa ja Ruotsissa

Regulatory

May 25, 2020

Nanoform announces a fixed subscription price and publishes a prospectus for its contemplated IPO and dual listing of its shares on Nasdaq First North Premier Growth Markets in Finland & Sweden

Regulatory

May 11, 2020

Nanoform intends to launch an initial public offering and dual listing on Nasdaq First North Premier Growth Markets in Finland & Sweden

Regulatory

May 11, 2020

Nanoform avser att genomföra ett erbjudande och att parallellnoteras på Nasdaq First North Premier Growth Market i Finland & Sverige

Regulatory

May 11, 2020

Nanoform harkitsee listautumisantia ja kaksoislistautumista Nasdaq First North Premier Growth Market Finland ja Sweden -markkinapaikoille

Non Regulatory

May 4, 2020

Nanoform awarded GMP certification

Non Regulatory

April 9, 2020

Nanoform appoints Miguel Calado as Chairman of the Board

Non Regulatory

March 9, 2020

Nanoform and Orion collaborate on next-generation drug development

Non Regulatory

February 10, 2020

Nanoform establishes US subsidiary

Non Regulatory

December 20, 2019

Nanoform files for GMP certification

Non Regulatory

November 6, 2019

Nanoform wins the CPhI Excellence in Pharma Award for Formulation

Non Regulatory

September 25, 2019

Nanoform and AstraZeneca Initiate Technology Evaluation

Non Regulatory

September 10, 2019

Nanoform strengthens board with appointment of Mads Laustsen

Non Regulatory

September 3, 2019

Nanoform appoints Mike Rea as Strategic Innovation Advisor

Non Regulatory

July 10, 2019

Nanoform appoints Director of Investor Relations following international growth

Non Regulatory

July 3, 2019

Nanoform continues strategic growth with €10 million private placement

Non Regulatory

June 27, 2019

Nanoform announces major rebrand

Non Regulatory

May 28, 2019

Nanoform accelerates growth with Director of Project Management appointment

Non Regulatory

May 28, 2019

Nanoform awarded with a Seal of Excellence from the European Commission

Non Regulatory

April 29, 2019

Nanoform strengthens GMP capabilities with Head of Manufacturing appointment

Non Regulatory

April 2, 2019

Nanoform strengthens board with appointment of Vice Chairman

Non Regulatory

March 5, 2019

Construction of Nanoform’s GMP manufacturing plant rapidly progresses

Non Regulatory

January 28, 2019

Nanoform signs world-leading sparse data AI expert

Non Regulatory

January 14, 2019

Nanoform set to boost world-class nanonization services with appointment of Chief Technology Officer

Non Regulatory

January 7, 2019

Nanoform significantly strengthens commercial organisation with Chief of Business Operations appointment

Non Regulatory

December 10, 2018

Nanoform continues rapid expansion with construction of GMP manufacturing plant

Non Regulatory

October 29, 2018

Nanoform set to globalize its technology with appointment of a Chief Commercial Officer

Non Regulatory

September 19, 2018

Nanoform set to transform drug development through €7 million investment in patented nanoparticle technology